ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension

Journal of Human Hypertension

Volumn 13, Issue 10, 1999, Pages 657-664

  Siche, J P ^a   Lacourciere Y ^b   Mallion, Jean Michel ^a  

^a HÔPITAL MICHALLON   (France)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

ABPM; Efficacy; Losartan; Telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; LOSARTAN; PLACEBO; TELMISARTAN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 0344289511     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000925     Document Type: Article

References (35)

1. Gavras I, Gavras H. Angiotensin II - possible adverse effects on arteries, heart, brain, and kidney: experimental, clinical, and epidemiological evidence. In: Robertson JIS, Nicholls MG (eds). The Renin-Angiotensin System, Vol 1. Gower Medical Publishing: London, 1993, pp 1-40.
2. Sowers JR, Epstein M. Diabetes mellitus and hypertension, emerging therapeutic perspectives. Cardiovasc Drug Rev 1995; 13: 149-210.
3. Lindgren BR, Andersson RG. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review. Med Toxicol Adverse Drug Exp 1989; 4: 369-380.
4. Sekizawa K et al. Role of substance P in cough. Pulm Pharmacol 1996; 9: 323-328.
5. Emanueli C et al. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 1998; 31: 1299-1304.
6. Dzau VJ. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. Basic Res Cardiol 1993; 88 (Suppl 1): 1-14.
7. Urata H et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91: 1269-1281.
8. Oliverio MI, Coffman TM. Angiotensin-II receptors: new targets for antihypertensive therapy. Clin Cardiol 1997; 20: 3-6.
9. Wienen W et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110: 245-252.
10. Van Meel JCA, Redemann N, Haigh RM. Hypotensive effects of the angiotensin II antagonist telmisartan in conscious chronically-instrumented transgenic rats. Arzneimittelforschung 1996; 46: 755-759.
11. Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT, receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15: 206-217.
12. Lacourcière Y et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monitor 1998; 3: 295-302.
13. Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998; 15: 229-240.
14. Zanchetti A. Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents. J Hypertens 1997; 15 (Suppl 7): S21-S25.
15. Pearce KA, Evans GW, Summerson J, Rao JS. Comparisons of ambulatory blood pressure monitoring and repeated office measurements in primary care. J Fam Pract 1997; 45: 426-433.
16. Dunnett CW, Tamhane AC. A step-up multiple test procedure. JASA 1992; 87: 162-170.
17. Dunnett CW, Tamhane AC. Step-down multiple tests for comparing treatments with a control in unbalanced one-way layouts. Stat Med 1991; 10: 939-947.
18. Waeber G et al. Comparison of betaxolol with verapamil in hypertensive patients: discrepancy between office and ambulatory blood pressures. J Hypertens 1998; 6: 329-245.
19. Pickering TG. A review of national guidelines on the clinical use of ambulatory blood pressure monitoring. Blood Press Monitor 1995; 1: 151-156.
20. Gosse PH, Ansoborlo P, Lemetayer PH, Clementy J. Left ventricular mass is better correlated with arising blood pressure than with office or occasional blood pressure. Am J Hypertens 1997; 10: 505-510.
21. Fogelholm RR et al. Diurnal blood pressure variations and onset of subarachnoidal haemorrhage: a population-based study. J Hypertens 1995; 13: 495-498.
22. Chasen C, Muller JE. Cardiovascular triggers and morning events. Blood Press Monitor 1998; 3: 35-42.
23. Weber MA et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995; 155: 405-411.
24. Byyny RL. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring. J Hypertens 1995; 13 (Suppl 1): S29-S33.
25. Mackay JH et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration with individual components. Arch Intern Med 1996; 156: 278-285.
26. Chau NP et al. Twenty-four hour ambulatory blood pressure in shift workers. Circulation 1989; 80: 341-347.
27. Fagard RH, Staessen JA, Thijs L. Optimal definition of daytime and nighttime blood pressure. Blood Press Monitor 1997; 2: 315-321.
28. White WB, Mansoor GA, Tendler BE, Anwar YA. Nocturnal blood pressure: epidemiology determinants and effects of antihypertensive therapy. Blood Press Monitor 1998; 3: 43-51.
29. Floras JS. Matinal blood pressure. Am J Hypertens 1992; 5: 411-413.
30. Mancia G et al. Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment: additional information from a large data base. Blood Press 1995; 4: 148-156.
31. Omboni S, Parati G, Zanchetti A, Mancia G. Calculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens 1995; 13: 1105-1112.
32. Siche JP et al. Individual smoothing of blood pressure profiles to define responders or non-responders to drugs. Blood Press Monitor 1996; 1: 263-266.
33. Leenen FH, Fourney A, Notman G, Tanner J. Persistence of anti-hypertensive effect after "missed doses" of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol 1996; 41: 83-88.
34. Nelson EB et al. Clinical profile of the first angiotensin II (AT-1 specific) receptor antagonists. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis, and Management, 2nd edn. Raven Press: New York, NY, 1995, pp 2895-2916.
35. Gradman AH et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-1350.